methyl 3-(methylamino)thiophene-2-carboxylate | 107818-58-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: methyl 3-(methylamino)thiophene-2-carboxylate
• 英文别名: methyl 3-mono-methylaminothiophene-2-carboxylate；Methyl 3-methylaminothiophene-2-carboxylate
• CAS: 107818-58-6
• 化学式: C₇H₉NO₂S
• 分子量: 171.22
• InChiKey: OSKPFMSGZDCERA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  66.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 3-(methylamino)thiophene-2-carboxylate 在 sodium hydroxide 、 水 、 sodium ethanolate 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 20.0h， 生成 2-(7-hydroxy-4-methyl-5-oxo-4,5-dihydrothieno[3,2-b]pyridine-6-carboxamido)acetic acid
  参考文献：
  名称：

  WO2008/137060

  摘要：

  公开号：
• 作为产物：
  描述：

  3-氨基-2-噻吩甲酸 在 4-二甲氨基吡啶 、 氯化亚砜 、 sodium hydride 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 26.5h， 生成 methyl 3-(methylamino)thiophene-2-carboxylate
  参考文献：
  名称：

  Scaffold Hopping of Natural Product Evodiamine: Discovery of a Novel Antitumor Scaffold with Excellent Potency against Colon Cancer

  摘要：

  Inspired by the natural product evodiamine, a novel antitumor indolopyrazinoquinazolinone scaffold was designed by scaffold hopping. Structure-activity relationship studies led to the discovery of compound 15j, which shows low nanomolar inhibitory activity against the HCT116 cell line. Further antitumor mechanism studies indicated that compound 15j acted by the dual inhibition of topoisomerase 1 and tubulin and induced apoptosis with G2 cell-cycle arrest. The quaternary ammonium salt of compound 15j (compound 15js) exhibited excellent in vivo antitumor activity (TGI = 66.6%) in the HCT116 xenograft model with low toxicity. Indolopyrazinoquinazolinone derivatives represent promising multitargeting antitumor leads for the development of novel antitumor agents.

  DOI：

  10.1021/acs.jmedchem.9b01626

文献信息

• Propionic Acid Derivatives and Methods of Use Thereof
  申请人：Biediger Ronald J.

  公开号：US20180312523A1

  公开（公告）日：2018-11-01

  Provided herein are compounds and pharmaceutical compositions of formula I where R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as described herein. Also provided pharmaceutically acceptable salts or stereoisomers of these compounds. In addition methods are provided for inhibiting the binding of an integrin to treat various pathophysiological conditions.

  本文提供了公式I的化合物和药物组合物，其中R1、R2、R3、R4、R5和R6如本文所述。还提供了这些化合物的药用可接受盐或立体异构体。此外，还提供了用于抑制整合素结合以治疗各种病理生理条件的方法。
• [EN] QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS<br/>[FR] DERIVES DE QUINOLEINE UTILISES EN TANT QU'INHIBITEURS DE LA PHOSPHODIESTERASE
  申请人：GLAXO GROUP LTD

  公开号：WO2004103998A1

  公开（公告）日：2004-12-02

  There are provided according to the invention novel compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R19, R20 and R34 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.

  根据本发明提供了化合物的新结构，其化学式为（I）或其药用盐，其中R1、R2、R19、R20和R34如规范中所述，以及制备这些化合物的方法、含有它们的配方和它们在治疗炎症性疾病中的用途。
• Anthranilamide and 2-amino-heteroarene-carboxamide compounds
  申请人：Conte Aurelia

  公开号：US20070219261A1

  公开（公告）日：2007-09-20

  Compounds of formula I processes for their preparation, their use as pharmaceuticals and to pharmaceutical compositions comprising them.

  化学式为I的化合物，制备它们的方法，它们作为药物的用途以及包含它们的药物组合物。
• Quinoline derivatives as phosphodiesterase inhibitors
  申请人：Baldwin Robert Ian

  公开号：US20070142373A1

  公开（公告）日：2007-06-21

  There are provided according to the invention novel compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R 1 , R 2, R 19, R 20, and R 34 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.

  根据本发明提供了新型化合物(I)的公式或其药学上可接受的盐，其中R1、R2、R19、R20和R34如规范所述，制备它们的过程，含有它们的配方以及它们在治疗炎症性疾病中的用途。
• Quinoline Derivatives As Phosphodiesterase Inhibitors
  申请人：Baldwin Ian Robert

  公开号：US20090312325A1

  公开（公告）日：2009-12-17

  There are provided according to the invention novel compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R19, R20, and R34 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.

  根据本发明提供了一种新的化合物式(I)或其药学上可接受的盐，其中R1、R2、R19、R20和R34如规范所述，以及制备它们的过程、含有它们的制剂以及它们在治疗炎症性疾病方面的用途。